The Icahn School of Medicine at Mount Sinai Joins NeuroNEXT Research Network Through Five-Year Grant From the National Institutes of Health
Innovative network designed to increase efficiency of neuroscience clinical trials for brain disorders
The Icahn School of Medicine at Mount Sinai (ISMMS) has joined the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT), a research program that helps streamline phase II clinical trials for brain disorders. NeuroNEXT is supported by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH).
“Earning a place in the NeuroNEXT network enables us to expand the collaborations taking place between basic and clinical brain researchers and experienced clinicians in numerous departments across the Mount Sinai Health System and with partners outside our institution,” says Barbara Vickrey, MD, MPH, Henry P. and Georgette Goldschmidt Professor and System Chair of Neurology. “Through this national network, we can build upon remarkable advances that have been achieved in studying the brain and spinal cord—many developed and put into practice at Mount Sinai—so that we can take what we learn at the bench and translate that knowledge into fundamentally new and improved treatments. We are well positioned to ensure timely, successful execution of these trials and are proud to be partnering with such an excellent cadre of research institutions that share a commitment to collaboration. Through this shared value and robust partnership, we can bring hope to the many patients and families who face devastating neurological conditions.”
Started in 2012 to make neuroscience clinical trials more efficient and to help increase the number of treatments that get into clinical practice, the NeuroNEXT program is designed to encourage collaborations between academic centers, disease foundations, and industry. Through this integrated network, participating academic medical centers will be able to enroll more patients in larger clinical trials and complete them more rapidly than each center could by itself.
Aaron Miller, MD, Professor of Neurology at ISMMS and Director of Clinical Affairs for The Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai, and Adilia Hormigo, MD, PhD, Associate Professor of Neurology, Medicine, and Neurosurgery at ISMMS and Director of the Neuro-Oncology Program at The Mount Sinai Hospital, will serve as Principal Investigators of the five-year NIH grant. Nathalie Jette, MD, MSc, Vice Chair for Clinical Research in the Department of Neurology at ISMMS, will serve as the Career Enhancement Director for junior/early stage investigator training for NeuroNEXT projects at Mount Sinai. The grant enables researchers from Mount Sinai to quickly mobilize with a diverse set of clinicians and experts from a wide range of disciplines to expedite clinical research so that treatments can get to patients faster.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City's largest integrated delivery system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Health System includes approximately 7,480 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Geriatrics, Gynecology, Nephrology, Neurology/Neurosurgery, and Orthopedics in the 2019-2020 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 12th nationally for Ophthalmology and Mount Sinai South Nassau is ranked 35th nationally for Urology. Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and Mount Sinai South Nassau are ranked regionally.